Forest Hills Lab Asking to Open Phase 2 Trial of FHL-301 in Parkinson’s
Forest Hills Lab announced plans to soon apply to the U.S. Food and Drug Administration (FDA) for permission to open a Phase 2 clinical trial evaluating the tolerability and efficacy of FHL-301 in people with Parkinson’s disease. FHL-301, or FHL CB-301, is reported to be a repurposed therapy…